Rhythm Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Rhythm Pharmaceuticals han disminuido a una tasa media anual de -15.4%, mientras que en la industria Biotechs los beneficios crecieron en un 15.5% anualmente. Los ingresos han ido creciendo a una tasa media de 83.8% al año.

Información clave

-15.4%

Tasa de crecimiento de los beneficios

-2.9%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	83.8%
Rentabilidad financiera	-444.7%
Margen neto	-297.9%
Última actualización de beneficios	31 Mar 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)

Jun 12

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

May 09

Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares May Have Run Too Fast Too Soon

May 05

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22

Mar 03

Rhythm Pharmaceuticals: Action Too Specific

Feb 23

Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price

Jan 08

We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely

Nov 03

We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate

Jul 23

Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Popularity With Investors Is Under Threat From Overpricing

Jun 17

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

May 05

Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans

Apr 01

An Intrinsic Calculation For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Suggests It's 46% Undervalued

Dec 15

We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Needs To Drive Business Growth Carefully

Oct 24

Rhythm Pharmaceuticals: Revisiting The Investment Thesis

Oct 10

Rhythm Pharmaceuticals announces $100M stock offering; shares fall 12% after hours

Sep 14

Rhythm Pharma's Imcivree drug gets expanded approval by European Commission for BBS

Sep 06

Industry Analysts Just Made An Incredible Upgrade To Their Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Revenue Forecasts

Aug 08

Rhythm Pharmaceuticals Q2 2022 Earnings Preview

Aug 01

Rhythm Pharma gains as NICE recommends obesity drug

Jul 18

Is Rhythm Pharmaceuticals (NASDAQ:RYTM) In A Good Position To Deliver On Growth Plans?

Jun 04

Desglose de ingresos y gastos

Cómo gana y gasta dinero Rhythm Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGM:RYTM Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Mar 24	92	-274	127	226
31 Dec 23	77	-185	118	135
30 Sep 23	62	-186	111	129
30 Jun 23	44	-182	103	116
31 Mar 23	34	-181	95	114
31 Dec 22	24	-181	92	109
30 Sep 22	17	-181	87	117
30 Jun 22	13	-176	82	123
31 Mar 22	5	-166	75	117
31 Dec 21	3	-70	68	104
30 Sep 21	1	-62	61	95
30 Jun 21	0	-60	54	90
31 Mar 21	0	-56	48	88
31 Dec 20	0	-134	46	90
30 Sep 20	0	-132	42	93
30 Jun 20	0	-134	42	97
31 Mar 20	0	-146	42	109
31 Dec 19	0	-141	37	109
30 Sep 19	0	-133	36	103
30 Jun 19	0	-115	34	88
31 Mar 19	0	-87	31	61
31 Dec 18	0	-74	28	50
30 Sep 18	0	-59	24	38
30 Jun 18	0	-53	18	33
31 Mar 18	0	-47	13	30
31 Dec 17	0	-38	10	23
30 Sep 17	0	-36	8	22
30 Jun 17	0	-32	7	21
31 Mar 17	0	-30	6	21
31 Dec 16	0	-29	6	20
30 Sep 16	0	-27	6	18
30 Jun 16	0	-23	6	14
31 Mar 16	0	-17	5	10
31 Dec 15	0	-12	3	7
30 Sep 15	0	-6	2	4
30 Jun 15	0	-3	1	2
31 Mar 15	0	-5	1	4
31 Dec 14	0	-6	1	5

Ingresos de calidad: RYTM actualmente no es rentable.

Margen de beneficios creciente: RYTM actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: RYTM no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 15.4% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de RYTM en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: RYTM no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (-14.4%).

Rentabilidad financiera

Alta ROE: RYTM tiene una rentabilidad financiera negativa (-444.73%), ya que actualmente no es rentable.

Rhythm Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Rhythm Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Rhythm Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)

New minor risk - Profitability

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Rhythm Pharmaceuticals, Inc. Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting

Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares May Have Run Too Fast Too Soon

Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in the Lancet Diabetes & Endocrinology

Rhythm Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2024

Rhythm Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Rhythm Pharmaceuticals, Inc. announced that it expects to receive $150 million in funding from Perceptive Advisors LLC, Discovery Real Estate Management

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

Executive VP & Head of North America notifies of intention to sell stock

Perceptive Advisors Engages in Discussion with Rhythm Pharmaceuticals

Consensus EPS estimates fall by 14%, revenue upgraded

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22

Consensus EPS estimates fall by 61%

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Rhythm Pharmaceuticals: Action Too Specific

Rhythm Pharmaceuticals, Inc. Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan

Chief Technical Officer notifies of intention to sell stock

New minor risk - Profitability

Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for Imcivree® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Price target increased by 9.0% to US$53.78

Price target increased by 10% to US$52.67

Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price

Forecast to breakeven in 2026

Chief Technical Officer notifies of intention to sell stock

Price target increased by 7.8% to US$47.67

CFO & Treasurer exercised options and sold US$860k worth of stock

Price target increased by 8.4% to US$44.22

CFO & Treasurer notifies of intention to sell stock

Chief Technical Officer notifies of intention to sell stock

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)

We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely

Rhythm Pharmaceuticals, Inc. Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome

Executive VP & Head of North America exercised options and sold US$180k worth of stock

Executive VP & Head of North America notifies of intention to sell stock

Consensus revenue estimates increase by 28%

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 19%

We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate

Rhythm Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Rhythm Pharmaceuticals, Inc. Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023

Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Popularity With Investors Is Under Threat From Overpricing

Rhythm Pharmaceuticals, Inc. Announces Approval of IMCIVREE®? Setmelanotide Solution for Weight Management in Adult and Pediatric Patients

Consensus EPS estimates fall by 10%

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans

Full year 2022 earnings released: US$3.48 loss per share (vs US$1.40 loss in FY 2021)

Price target increased by 8.6% to US$36.56

Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome

An Intrinsic Calculation For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Suggests It's 46% Undervalued

Rhythm Pharmaceuticals Announces ?Imcivree (Setmelanotide) Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

Price target increased to US$33.44

Price target increased to US$33.00

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 3 Clinical Trial of IMCIVREE in Bardet-Biedl Syndrome in The Lancet Diabetes and Endocrinology

Rhythm Pharmaceuticals Presents Data from Phase 2 and Long-Term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity At Obesityweek® and Plans to Initiate Phase 3 Trial in Early 2023

Rhythm Pharmaceuticals, Inc. Announces Setmelanotide Granted Breakthrough Therapy Designation for Hypothalamic Obesity by the U.S. FDA

We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Needs To Drive Business Growth Carefully

Rhythm Pharmaceuticals: Revisiting The Investment Thesis

Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development

Rhythm Pharmaceuticals Presents New Disease Burden Findings and Analyses of Setmelanotide Data in Children and Adolescents with Rare MC4R Pathway Diseases at ESPE 2022

Rhythm Pharmaceuticals announces $100M stock offering; shares fall 12% after hours

Rhythm Pharmaceuticals, Inc. Announces European Commission Expands the Marketing Authorization for Imcivree(R) (Setmelanotide)

Rhythm Pharma's Imcivree drug gets expanded approval by European Commission for BBS